Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX210 single-ascending-dose placebo-controlled study in healthy volunteers
NL-OMON49076Active, not recruiting
- Sponsor
- Axoltis Pharma
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial in spinal cord injury (SCI) and neurological diseases comparing NX210 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2020; status: active, not recruiting.
02
Drugs
nx210c
03
Conditions
spinal cord injury (SCI)neurological diseases
Beyond the preview
Go deeper on NL-OMON49076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49076.